www.swissinfo.ch
Roche acquires Chinese antibody-drug conjugate rights for $500m
Roche acquires rights to portfolio of antibody-drug conjugates (ADCs) by Chinese competitor Hansoh Pharma.
#Roche is an active hashtag on Bluesky. In the last 30 days, 27 people shared 55 posts with it — around 2 a day. Activity is up 43% versus the previous week, peaking on Oct 19 with 9 posts.
Tags most often used together with #Roche.
statnews.com
Pharmalittle: We're reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny
dlvr.it
Roche just bet up to $15B on China's cancer drug tech
Roche's massive licensing deal with Hansoh Pharmaceutical signals how aggressively Western pharma giants are tapping Chinese biotech innovation — even as geopolitical tensions simmer. The agreement is part of a broader dealmaking surge: Chinese drug developers inked 81 licensing deals worth up to $110 billion in just the first half of 2026.
pharmaphorum.com
Roche offers $15bn for strategic-level deal with Hansoh
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.
dlvr.it
Roche just bet up to $15B on China's cancer drug tech
Roche's massive licensing deal with Hansoh Pharmaceutical signals how aggressively Western pharma giants are tapping Chinese biotech innovation — even as geopolitical tensions simmer. The agreement is part of a broader dealmaking surge: Chinese drug developers inked 81 licensing deals worth up to $110 billion in just the first half of 2026.
statnews.com
Pharmalittle: We're reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny
dlvr.it
Roche just bet up to $15B on China's cancer drug tech
Roche's massive licensing deal with Hansoh Pharmaceutical signals how aggressively Western pharma giants are tapping Chinese biotech innovation — even as geopolitical tensions simmer. The agreement is part of a broader dealmaking surge: Chinese drug developers inked 81 licensing deals worth up to $110 billion in just the first half of 2026.
pharmaphorum.com
Roche offers $15bn for strategic-level deal with Hansoh
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.
dlvr.it
Roche just bet up to $15B on China's cancer drug tech
Roche's massive licensing deal with Hansoh Pharmaceutical signals how aggressively Western pharma giants are tapping Chinese biotech innovation — even as geopolitical tensions simmer. The agreement is part of a broader dealmaking surge: Chinese drug developers inked 81 licensing deals worth up to $110 billion in just the first half of 2026.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.